Press Releases
View printer-friendly version << Back
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Presentation details: | ||
Date: | ||
Time: | ||
Webcast: | A live and archived webcast of the presentation will be available at (click here) or on the Company’s website (click here) | |
In addition, management will be participating in one-on-one meetings with investors who are registered to attend the conference.
About Avadel Pharmaceuticals plc:
About FT218
FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. The Company recently completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.
Contacts:
Investor Contacts Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.com Phone: (212) 915-2564 Email: tim@lifesciadvisors.com Media Contact Phone: (646) 970-4688 Email: pbursey@lifescicomms.com |
Source: Avadel Pharmaceuticals plc